Quantcast

Latest Antigenics Inc. Stories

2008-11-05 09:00:34

Antigenics Inc. (NASDAQ: AGEN) reported results for the quarter ended September 30, 2008. The company incurred a net loss attributable to common stockholders of $11.1 million, or $0.17 per share, basic and diluted, for the third quarter of 2008, compared with a net loss attributable to common stockholders in the third quarter of 2007 of $11.0 million, or $0.24 per share, basic and diluted. For the nine months ended September 30, 2008, the company incurred a net loss attributable to common...

2008-11-03 09:00:39

Antigenics Inc. (NASDAQ: AGEN) today announced that Garo Armen, Ph.D., the company's chairman and chief executive officer, will present at the Rodman and Renshaw 10th Annual Healthcare Conference at the Palace Hotel in New York on Monday, November 10, 2008 at 12:25 p.m. Eastern Time. Dr. Armen will provide an overview of the company and its priority development programs, including Oncophage(R) (vitespen) therapeutic cancer vaccine and QS-21(TM) vaccine adjuvant. The audio portion of...

2008-10-23 12:00:26

Antigenics, a biotechnology company, has submitted a marketing authorization application to the European Medicines Agency requesting approval for Oncophage in earlier-stage, localized renal cell carcinoma under the conditional authorization provision. In advance of the marketing authorization application (MAA) submission, meetings with European Medicines Agency (EMEA) representatives, including the rapporteur countries, were convened to discuss the results from the international,...

2008-10-22 06:00:08

Antigenics Inc. (NASDAQ: AGEN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) requesting approval for Oncophage(R) in earlier-stage, localized renal cell carcinoma (kidney cancer) under the conditional authorization provision. Currently, there are no EMEA-approved drug therapies for this patient population. "The creation of the EMEA's conditional approval regulation provides an important mechanism for allowing patients...

2008-09-30 09:01:00

Antigenics, a biotechnology company, has announced that the FDA has granted the necessary permission to allow for the export of Oncophage to Russia. The FDA export license clears the way to provide patients in Russia with Oncophage, which will continue to be manufactured at the company's facility in Lexington, Massachusetts. The Russian Ministry of Public Health approved the therapeutic cancer vaccine in April 2008 for the adjuvant treatment of kidney cancer patients at intermediate risk...

2008-09-29 12:00:14

Antigenics Inc. (NASDAQ: AGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted the necessary permission to allow for the export of Oncophage (R) (vitespen) to Russia. The Russian Ministry of Public Health approved the therapeutic cancer vaccine in April 2008 for the adjuvant treatment of kidney cancer patients at intermediate risk for disease recurrence. The FDA export license clears the way to provide patients in Russia with Oncophage, which will continue to...

2008-09-15 09:00:58

Antigenics Inc. (NASDAQ: AGEN) today announced that Garo Armen, Ph.D., the company's chairman and chief executive officer, will present at the UBS 2008 Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 22, 2008 at 8:00 a.m. Eastern Time. Dr. Armen will provide an overview of the company and its priority development programs, including Oncophage(R) (vitespen) therapeutic cancer vaccine and QS-21(TM) vaccine adjuvant. The audio portion of the...

2008-07-31 09:01:26

Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended June 30, 2008. The company incurred a net loss attributable to common stockholders of $12.2 million, or $0.19 per share, basic and diluted, for the second quarter of 2008, compared with a net loss attributable to common stockholders in the second quarter of 2007 of $10.1 million, or $0.22 per share, basic and diluted. For the six months ended June 30, 2008, Antigenics incurred a net loss attributable to common...

2008-07-24 09:01:13

CAMBRIDGE, Mass., July 24, 2008 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Bruce A. Leicher, J.D. has been appointed as the Company's Senior Vice President and General Counsel. Craig A. Wheeler, CEO of Momenta, commented, "Bruce brings nearly 20 years of legal experience in the biotechnology industry to Momenta, and we are very pleased to have him join...

2005-10-10 11:15:12

NEW YORK (Reuters) - Antigenics Inc. said on Monday a preliminary analysis showed its Oncophage skin cancer vaccine failed to meet the primary goal of a trial, but appeared to prolong survival in a group of patients, lifting shares 18 percent. Overall, those in the 322-patient trial taking Oncophage fared no better than those taking standard cancer treatments in terms of survival. But a previously defined group of patients with the least-advanced severity of melanoma in the trial...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related